The Potential of a Placebo/Nocebo Effect in Pharmacogenetics
Pharmacogenetic testing holds great promise to improve health outcomes and reduce adverse drug responses through enhanced selection of therapeutic agents. Since drug responses can be manipulated by verbal suggestions, it is of particular interest to understand the potential impact of pharmacogenetic...
Gespeichert in:
Veröffentlicht in: | Community genetics 2009-01, Vol.12 (3), p.158-162 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 162 |
---|---|
container_issue | 3 |
container_start_page | 158 |
container_title | Community genetics |
container_volume | 12 |
creator | Haga, S.B. Warner, L.R. O’Daniel, J. |
description | Pharmacogenetic testing holds great promise to improve health outcomes and reduce adverse drug responses through enhanced selection of therapeutic agents. Since drug responses can be manipulated by verbal suggestions, it is of particular interest to understand the potential impact of pharmacogenetic test results on drug response. Placebo and nocebo-like effects may be possible due to the suggestive nature of pharmacogenetic information that a drug will or will not likely lead to improved health outcomes. For example, pharmacogenetic testing could provide further reassurance to patients that a given drug will be effective and/or cause minimal side effects. However, pharmacogenetic information could adversely affect drug response through negative expectations that a drug will be less than optimally effective or cause an adverse response, known as a nocebolike effect. Therefore, a patient’s perceived value of testing, their understanding of the test results, and the manner in which they are communicated may influence therapeutic outcome. As such, physicians should consider the potential effect of pharmacogenetic test results on therapeutic outcome when communicating results to patients. Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome. |
doi_str_mv | 10.1159/000189628 |
format | Article |
fullrecord | <record><control><sourceid>jstor_karge</sourceid><recordid>TN_cdi_karger_primary_189628</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26686488</jstor_id><sourcerecordid>26686488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-1fcc0f5833d964850939f0f0141e32040d3ee49aa371d45c3a4c498bca03866e3</originalsourceid><addsrcrecordid>eNqFkUtvEzEUhU0B9QUL9hSNWCCxCL1-zB1bQpVQVR5SBVmUteU418mkk3FrTyrx73GVkJRuurqL8_no-BzG3nD4xHltTgGAa4NCP2NHUkNdG0Dge-yQI4qRBpTPt0Jt9IuNoITCA3aU8wIAFQLuswNuBCjF9SH7fDWnahwH6ofWdVUMlavGnfM0iac_4_2pLkIgP1RtX43nLi2djzPqaWh9fsVeBtdler25x-z314ur8--jy1_ffpx_uRx51ahhxIP3EGot5dSg0jUYaQIE4IqTLEFgKomUcU42fKpqL53yyuiJdyA1Isljdrb2vVlNljT1JWxynb1J7dKlPza61v6v9O3czuKdFY3UuhHF4MPGIMXbFeXBLtvsqetcT3GVLaIBw0X9JCjACM1RF_D9I3ARV6kvLViERpRyAQr0cQ35FHNOFLaROdj7Te1208K-e_jHHbmZqgBv18C1SzNKO-Df-5O1vMhD3KkCUZfOtfwLNgqoFg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>607244100</pqid></control><display><type>article</type><title>The Potential of a Placebo/Nocebo Effect in Pharmacogenetics</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Haga, S.B. ; Warner, L.R. ; O’Daniel, J.</creator><creatorcontrib>Haga, S.B. ; Warner, L.R. ; O’Daniel, J.</creatorcontrib><description>Pharmacogenetic testing holds great promise to improve health outcomes and reduce adverse drug responses through enhanced selection of therapeutic agents. Since drug responses can be manipulated by verbal suggestions, it is of particular interest to understand the potential impact of pharmacogenetic test results on drug response. Placebo and nocebo-like effects may be possible due to the suggestive nature of pharmacogenetic information that a drug will or will not likely lead to improved health outcomes. For example, pharmacogenetic testing could provide further reassurance to patients that a given drug will be effective and/or cause minimal side effects. However, pharmacogenetic information could adversely affect drug response through negative expectations that a drug will be less than optimally effective or cause an adverse response, known as a nocebolike effect. Therefore, a patient’s perceived value of testing, their understanding of the test results, and the manner in which they are communicated may influence therapeutic outcome. As such, physicians should consider the potential effect of pharmacogenetic test results on therapeutic outcome when communicating results to patients. Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome.</description><identifier>ISSN: 1662-4246</identifier><identifier>ISBN: 3805590598</identifier><identifier>ISBN: 9783805590594</identifier><identifier>EISSN: 1662-8063</identifier><identifier>EISBN: 3805590601</identifier><identifier>EISBN: 9783805590600</identifier><identifier>DOI: 10.1159/000189628</identifier><identifier>PMID: 19204418</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Clinical Trials as Topic ; Humans ; Pharmaceutical Preparations ; Pharmacogenetics ; Placebo Effect ; Side effects ; Treatment Outcome</subject><ispartof>Community genetics, 2009-01, Vol.12 (3), p.158-162</ispartof><rights>2009 S. Karger AG</rights><rights>2009 S. Karger AG, Basel</rights><rights>Copyright 2009 S. Karger AG, Basel.</rights><rights>Copyright (c) 2009 S. Karger AG, Basel</rights><rights>Copyright © 2009 by S. Karger AG, Basel 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-1fcc0f5833d964850939f0f0141e32040d3ee49aa371d45c3a4c498bca03866e3</citedby><cites>FETCH-LOGICAL-c474t-1fcc0f5833d964850939f0f0141e32040d3ee49aa371d45c3a4c498bca03866e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26686488$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26686488$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,2422,27903,27904,57996,58229</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19204418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haga, S.B.</creatorcontrib><creatorcontrib>Warner, L.R.</creatorcontrib><creatorcontrib>O’Daniel, J.</creatorcontrib><title>The Potential of a Placebo/Nocebo Effect in Pharmacogenetics</title><title>Community genetics</title><addtitle>Public Health Genomics</addtitle><description>Pharmacogenetic testing holds great promise to improve health outcomes and reduce adverse drug responses through enhanced selection of therapeutic agents. Since drug responses can be manipulated by verbal suggestions, it is of particular interest to understand the potential impact of pharmacogenetic test results on drug response. Placebo and nocebo-like effects may be possible due to the suggestive nature of pharmacogenetic information that a drug will or will not likely lead to improved health outcomes. For example, pharmacogenetic testing could provide further reassurance to patients that a given drug will be effective and/or cause minimal side effects. However, pharmacogenetic information could adversely affect drug response through negative expectations that a drug will be less than optimally effective or cause an adverse response, known as a nocebolike effect. Therefore, a patient’s perceived value of testing, their understanding of the test results, and the manner in which they are communicated may influence therapeutic outcome. As such, physicians should consider the potential effect of pharmacogenetic test results on therapeutic outcome when communicating results to patients. Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome.</description><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmacogenetics</subject><subject>Placebo Effect</subject><subject>Side effects</subject><subject>Treatment Outcome</subject><issn>1662-4246</issn><issn>1662-8063</issn><isbn>3805590598</isbn><isbn>9783805590594</isbn><isbn>3805590601</isbn><isbn>9783805590600</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUtvEzEUhU0B9QUL9hSNWCCxCL1-zB1bQpVQVR5SBVmUteU418mkk3FrTyrx73GVkJRuurqL8_no-BzG3nD4xHltTgGAa4NCP2NHUkNdG0Dge-yQI4qRBpTPt0Jt9IuNoITCA3aU8wIAFQLuswNuBCjF9SH7fDWnahwH6ofWdVUMlavGnfM0iac_4_2pLkIgP1RtX43nLi2djzPqaWh9fsVeBtdler25x-z314ur8--jy1_ffpx_uRx51ahhxIP3EGot5dSg0jUYaQIE4IqTLEFgKomUcU42fKpqL53yyuiJdyA1Isljdrb2vVlNljT1JWxynb1J7dKlPza61v6v9O3czuKdFY3UuhHF4MPGIMXbFeXBLtvsqetcT3GVLaIBw0X9JCjACM1RF_D9I3ARV6kvLViERpRyAQr0cQ35FHNOFLaROdj7Te1208K-e_jHHbmZqgBv18C1SzNKO-Df-5O1vMhD3KkCUZfOtfwLNgqoFg</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Haga, S.B.</creator><creator>Warner, L.R.</creator><creator>O’Daniel, J.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090101</creationdate><title>The Potential of a Placebo/Nocebo Effect in Pharmacogenetics</title><author>Haga, S.B. ; Warner, L.R. ; O’Daniel, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-1fcc0f5833d964850939f0f0141e32040d3ee49aa371d45c3a4c498bca03866e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmacogenetics</topic><topic>Placebo Effect</topic><topic>Side effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haga, S.B.</creatorcontrib><creatorcontrib>Warner, L.R.</creatorcontrib><creatorcontrib>O’Daniel, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Community genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haga, S.B.</au><au>Warner, L.R.</au><au>O’Daniel, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Potential of a Placebo/Nocebo Effect in Pharmacogenetics</atitle><jtitle>Community genetics</jtitle><addtitle>Public Health Genomics</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>12</volume><issue>3</issue><spage>158</spage><epage>162</epage><pages>158-162</pages><issn>1662-4246</issn><eissn>1662-8063</eissn><isbn>3805590598</isbn><isbn>9783805590594</isbn><eisbn>3805590601</eisbn><eisbn>9783805590600</eisbn><abstract>Pharmacogenetic testing holds great promise to improve health outcomes and reduce adverse drug responses through enhanced selection of therapeutic agents. Since drug responses can be manipulated by verbal suggestions, it is of particular interest to understand the potential impact of pharmacogenetic test results on drug response. Placebo and nocebo-like effects may be possible due to the suggestive nature of pharmacogenetic information that a drug will or will not likely lead to improved health outcomes. For example, pharmacogenetic testing could provide further reassurance to patients that a given drug will be effective and/or cause minimal side effects. However, pharmacogenetic information could adversely affect drug response through negative expectations that a drug will be less than optimally effective or cause an adverse response, known as a nocebolike effect. Therefore, a patient’s perceived value of testing, their understanding of the test results, and the manner in which they are communicated may influence therapeutic outcome. As such, physicians should consider the potential effect of pharmacogenetic test results on therapeutic outcome when communicating results to patients. Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>19204418</pmid><doi>10.1159/000189628</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1662-4246 |
ispartof | Community genetics, 2009-01, Vol.12 (3), p.158-162 |
issn | 1662-4246 1662-8063 |
language | eng |
recordid | cdi_karger_primary_189628 |
source | MEDLINE; Jstor Complete Legacy; Karger Journals; Alma/SFX Local Collection |
subjects | Clinical Trials as Topic Humans Pharmaceutical Preparations Pharmacogenetics Placebo Effect Side effects Treatment Outcome |
title | The Potential of a Placebo/Nocebo Effect in Pharmacogenetics |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A40%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Potential%20of%20a%20Placebo/Nocebo%20Effect%20in%20Pharmacogenetics&rft.jtitle=Community%20genetics&rft.au=Haga,%20S.B.&rft.date=2009-01-01&rft.volume=12&rft.issue=3&rft.spage=158&rft.epage=162&rft.pages=158-162&rft.issn=1662-4246&rft.eissn=1662-8063&rft.isbn=3805590598&rft.isbn_list=9783805590594&rft_id=info:doi/10.1159/000189628&rft_dat=%3Cjstor_karge%3E26686488%3C/jstor_karge%3E%3Curl%3E%3C/url%3E&rft.eisbn=3805590601&rft.eisbn_list=9783805590600&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=607244100&rft_id=info:pmid/19204418&rft_jstor_id=26686488&rfr_iscdi=true |